Life Biosciences begins clinical trials for ER-100, an OSK gene therapy aimed at reversing age-related vision loss and cellular degeneration.
Immortality is no longer just a fantasy in movies like The Age of Adaline or Interstellar; it is edging closer to reality as scientists pioneer genetic reprogramming. Rather than just delaying the inevitable, researchers are discovering how to reverse biological age at a cellular level. This represents a paradigm shift in how medicine views chronic age-related degeneration (1✔ ✔Trusted Source
Reprogramming to recover youthful epigenetic information and restore vision
)(3✔ ✔Trusted Source
Organ-Specific Dedifferentiation and Epigenetic Remodeling in In Vivo Reprogramming
).
Advertisement
What is OSK Gene Therapy? Reversing Biological Aging in Human Eye Trials
The breakthrough therapy, known as ER-100, was developed by co-founder Dr. David Sinclair of Harvard University. The platform delivers three of the four classic Yamanaka factors—specifically OCT4, SOX2, and KLF4, abbreviated as OSK. In January 2026, the company Life Biosciences received Food and Drug Administration (FDA) clearance for human clinical testing (2✔ ✔Trusted Source
The Pathway From Genes to Gene Therapy in Glaucoma: A Review of Possibilities for Using Genes as Glaucoma Drugs
)(3✔ ✔Trusted Source
Organ-Specific Dedifferentiation and Epigenetic Remodeling in In Vivo Reprogramming
).
Advertisement
David Sinclair’s Information Theory of Aging and the ER-100 Breakthrough
This research is based on Sinclair’s information theory of aging, which posits that cells age because they lose their epigenetic memory. Over time, cells lose the ability to read their DNA accurately, leading to systemic cellular dysfunction and organ degeneration. Reintroducing the OSK genes allows cells to access their original genetic instructions, reversing cellular age by about 75% (1✔ ✔Trusted Source
Reprogramming to recover youthful epigenetic information and restore vision
).
Advertisement
Preclinical Findings: Restoring Vision in Mice and Non-Human Primates
Before moving to human trials, this approach was extensively tested in mice and non-human primates to ensure its safety. The therapy successfully restored vision in glaucoma models and reversed optic nerve damage without triggering tumor growth or oncogenic mutations. Rejuvenation is controlled using a doxycycline switch, allowing scientists to turn the therapeutic expression on or off as needed (1✔ ✔Trusted Source
Reprogramming to recover youthful epigenetic information and restore vision
)(2✔ ✔Trusted Source
The Pathway From Genes to Gene Therapy in Glaucoma: A Review of Possibilities for Using Genes as Glaucoma Drugs
).
Phase 1 Clinical Trials: The Future of Epigenetic Restoration
In June 2026, the first human patient was dosed in a trial targeting open-angle glaucoma (OAG). The study also targets patients suffering from non-arteritic anterior ischemic optic neuropathy (NAION), a leading cause of sudden vision loss. If successful, this trial could pave the way for broad epigenetic therapies that reverse aging throughout the entire body (2✔ ✔Trusted Source
The Pathway From Genes to Gene Therapy in Glaucoma: A Review of Possibilities for Using Genes as Glaucoma Drugs
)(3✔ ✔Trusted Source
Organ-Specific Dedifferentiation and Epigenetic Remodeling in In Vivo Reprogramming
).
References:
- Reprogramming to recover youthful epigenetic information and restore vision – (https://pubmed.ncbi.nlm.nih.gov/33268865/)
- Gene therapy for glaucoma: A review – (https://pubmed.ncbi.nlm.nih.gov/30252388/)
- Yamanaka factors and epigenetic rejuvenation – (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202392/)
Source-Medindia